Results 131 to 140 of about 1,942 (154)
A Vector Theory of Assessing Clinical Trials: An Application to Bioequivalence. [PDF]
Karalis VD.
europepmc +1 more source
PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report. [PDF]
Heimbach T +40 more
europepmc +1 more source
Leveraging Model Master Files for Long-Acting Injectables. [PDF]
Gong Y +9 more
europepmc +1 more source
Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended-Release and Immediate-Release Formulations in Healthy Adults Using the Quantitative Systems Toxicology Software Platform DILIsym. [PDF]
Beaudoin JJ +9 more
europepmc +1 more source
openaire
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The AAPS Journal, 2023
In lieu of large bioequivalence studies and exposing healthy postmenopausal women to additional drug exposure for elagolix coadministered with hormonal add-back therapy, physiologically based pharmacokinetic (PBPK) modeling was used with in vitro dissolution data to test for virtual bioequivalence.
Dwaipayan Mukherjee +5 more
openaire +4 more sources
In lieu of large bioequivalence studies and exposing healthy postmenopausal women to additional drug exposure for elagolix coadministered with hormonal add-back therapy, physiologically based pharmacokinetic (PBPK) modeling was used with in vitro dissolution data to test for virtual bioequivalence.
Dwaipayan Mukherjee +5 more
openaire +4 more sources
Clinical Pharmacokinetics, 2021
Model-informed drug discovery and development (MID3) shows great advantages in facilitating drug development. A physiologically based pharmacokinetic model is one of the powerful computational approaches of MID3, and the emerging field of virtual bioequivalence is well recognized to be the future of the physiologically based pharmacokinetic model ...
Fan Zhang +5 more
openaire +4 more sources
Model-informed drug discovery and development (MID3) shows great advantages in facilitating drug development. A physiologically based pharmacokinetic model is one of the powerful computational approaches of MID3, and the emerging field of virtual bioequivalence is well recognized to be the future of the physiologically based pharmacokinetic model ...
Fan Zhang +5 more
openaire +4 more sources
Journal of Pharmaceutical Sciences, 2022
The objective of the present study was to develop a physiologically based biopharmaceutics (PBBM) approach to predict the bioequivalence of dosage forms containing poorly soluble drugs. Aripiprazole and enzalutamide were used as model drugs. Variations in the gastrointestinal (GI) physiological parameters of fasted humans were taken into consideration ...
Atsushi, Kambayashi +1 more
openaire +4 more sources
The objective of the present study was to develop a physiologically based biopharmaceutics (PBBM) approach to predict the bioequivalence of dosage forms containing poorly soluble drugs. Aripiprazole and enzalutamide were used as model drugs. Variations in the gastrointestinal (GI) physiological parameters of fasted humans were taken into consideration ...
Atsushi, Kambayashi +1 more
openaire +4 more sources
Molecular Pharmaceutics, 2022
To evaluate the influence of solubility and permeability on the pharmacokinetic prediction performance of orally administered drugs using avirtual bioequivalence (VBE) model, a total of 23 orally administered drugs covering Biopharmaceutics Classification System (BCS) classes 1-4 were selected. A VBE model (i.e., a physiologically based pharmacokinetic
Fan Zhang +5 more
openaire +2 more sources
To evaluate the influence of solubility and permeability on the pharmacokinetic prediction performance of orally administered drugs using avirtual bioequivalence (VBE) model, a total of 23 orally administered drugs covering Biopharmaceutics Classification System (BCS) classes 1-4 were selected. A VBE model (i.e., a physiologically based pharmacokinetic
Fan Zhang +5 more
openaire +2 more sources

